Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07068945

Study of the Transition From Child Psychiatry to Adult Psychiatry in Nice Within a Population of 17-year-old Adolescents

Transitional psychiatry addresses the complex process through which individuals move from adolescence to adulthood, both in terms of developmental stage and mental healthcare systems. This transition includes the shift from pediatric to adult psychiatric services, as well as the evolution from vague or subclinical symptoms to established psychiatric disorders that may become chronic without early intervention.

Psychiatric disorders often emerge early in life: approximately 50% before age 15 and 75% before age 25. Early detection and intervention are therefore crucial to improving long-term mental health outcomes, functional independence, and social integration. However, current healthcare systems frequently fail to meet the needs of adolescents and young adults during this critical transition phase. Organizational discontinuities and clinical complexity lead to several risks:

* Difficulties in accessing appropriate psychiatric care for adolescents presenting with emerging symptoms, * High rates of service disengagement for patients already receiving pediatric mental health care who do not successfully transition to adult services.

Studies have shown that nearly half (48%) of young people drop out of psychiatric follow-up for at least three months after reaching adulthood. This interruption increases the likelihood of relapse and involuntary psychiatric admissions. Despite numerous publications over the past decade emphasizing the need for dedicated transitional care models, services remain fragmented in many systems.

One of the largest recent studies in this area, the European MILESTONE longitudinal study, followed 763 patients (mean age 17.5) over two years in eight countries. It found that 11% of participants discontinued care entirely, 41% experienced discontinuity, and only 21% successfully transitioned to adult psychiatry. Continued care was more likely among patients with severe psychiatric disorders who had already accepted treatment. In contrast, those with mood disorders or poorly defined symptoms-despite being at high risk-were less likely to receive ongoing support.

Transitional psychiatry therefore aims to establish integrated practices and systems that ensure the continuity of mental healthcare for youth aged approximately 16 to 25. The main objectives of such services are to:

* Prevent care disruptions at the age of majority, * Maintain appropriate and developmentally sensitive treatment for young adults, * Promote patient autonomy in managing their care, * Ensure coordination and collaboration between child/adolescent and adult psychiatric teams.

Despite growing recognition of these needs, no consensus exists in the literature regarding a fixed duration that defines a true care discontinuity, and practices vary significantly between regions and systems.

In this context, the Odyssée 3 project was launched in Nice, France, as a prospective epidemiological study focusing specifically on the real-life transition from child and adolescent psychiatry to adult psychiatry. The study targets a cohort of 17-year-olds who are currently receiving mental health care and will soon face the shift to adult services.

The project is part of the CNR Santé Mentale territorial initiative, supported by the Regional Health Agency (ARS 06). It is co-led by the University Department of Child and Adolescent Psychiatry (SUPEA) at Lenval Pediatric University Hospital and the Department of Psychiatry at the Nice University Hospital (CHU de Nice).

Odyssey 3 has three primary goals:

* To assess the care pathways and clinical outcomes of adolescents undergoing transition to adult psychiatry; * To identify patient profiles, trajectories, and risk factors associated with successful or failed care continuity; * To generate data that will inform the creation of a dedicated transitional psychiatry team and pathway in the Nice area.

Ultimately, this study aims to strengthen the healthcare system's ability to detect early warning signs, intervene proactively in emerging psychiatric conditions, and ensure that adolescents already engaged in care do not experience service discontinuities. Its findings will serve as a foundation for building a specialized, coordinated, and sustainable transitional psychiatry structure in Nice, aligned with best practices and international recommendations.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

17 year–17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Fondation Lenval Hôpitaux pédiatrique Nice CHU Lenval

Nice, 06200, France

Location status: Recruiting

Location contact

Louise -Emilie Dumas, MD

CONTACT

[email protected]

+33(0)4 92 03 03 26

Louise- Emilie Dumas, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants must meet all of the following criteria:

  • Age ≥17 and <18 years at inclusion.
  • Receiving care (outpatient, inpatient, or emergency) within the Child and Adolescent Psychiatry Department at Lenval University Children's Hospital.
  • Presence of a psychiatric disorder according to DSM-5 criteria, irrespective of diagnostic category.
  • Considered to be in a potential transition situation to adult mental health services within the following 12 months.
  • Living in the municipality of Nice (postal codes 06000, 06100, 06200, 06300).
  • Able to provide written informed consent, together with at least one parent or legal guardian.

Exclusion criteria

Participants meeting any of the following criteria will be excluded:

  • Insufficient command of French preventing comprehension of study information or completion of questionnaires.
  • Cognitive or sensory impairments (e.g. moderate-to-severe intellectual disability, major visual impairment, severe reading difficulties) preventing valid completion of assessments.
  • Legal incapacity (e.g. guardianship) preventing independent consent.
  • Acute or unstable clinical condition requiring urgent or intensive care incompatible with research participation (e.g. severe psychiatric decompensation, immediate suicidal crisis).
  • Refusal to participate by the adolescent or the parent(s)/legal representative(s).
  • Any situation judged by the investigator as incompatible with one-year follow-up (e.g. imminent transfer to another region).

Treatment and study plan

Group of 17-year-old patients living in Nice and receiving psychiatric care

Behavioral

Prospective study aiming to determine the annual prevalence of 17-year-old patients living in Nice who attend hospital-based child and adolescent psychiatry services. Secondary objectives include: estimating prevalence among under-18 psychiatric patients; describing clinical and sociodemographic profiles (sample of 100 patients); mapping 1-year care trajectories; evaluating clinical outcomes; assessing transition preparedness (to adult psychiatry); and identifying factors associated with psychiatric care continuity at 12 months.

Primary outcomes

  1. Annual prevalence of 17-year-old patients living in Nice who consulted hospital-based child and adolescent psychiatry services, calculated against the total number of 17-year-olds in the general population of Nice.

    Time frame: one year

    Annual prevalence is defined as the number of 17-year-old patients living in the city of Nice who consult hospital-based child and adolescent psychiatry services within a one-year period, divided by the total number of 17-year-olds in the general population of Nice. The calculation was performed using data from INSEE (French National Institute of Statistics and Economic Studies).

Secondary outcomes

  1. Annual Prevalence of 17-Year-Old Adolescents Consulting Child and Adolescent Psychiatric Services in Nice

    Time frame: One year following the first psychiatric consultation during the study period.

    The annual prevalence is defined as the proportion of 17-year-old adolescents living in the municipality of Nice who consulted the child and adolescent psychiatric hospital services at HPU Lenval during a given year, among all minors (<18 years) living in Nice who had at least one psychiatric consultation at HPU Lenval during the same year.

  2. Baseline Description of Patient Profiles in a Child and Adolescent Psychiatric Population

    Time frame: Baseline

    This outcome corresponds to a detailed baseline characterization of the study population based on a sample of 100 patients specifically included in the study. Predefined socio-demographic and medical characteristics were collected and analyzed.

  3. One-Year Psychiatric Care Trajectories in Adolescents

    Time frame: 12 months after study inclusion

    The one-year care trajectory of patients will be assessed according to changes in their psychiatric management during follow-up. At 12 months (M12), patients will be classified into the following categories: continuation of care in child and adolescent psychiatry, transition to adult psychiatry services, discontinuity or interruption/resumption of care, planned termination of care agreed upon by the patient and medical team, or lost to follow-up.

  4. Clinical Evolution

    Time frame: Baseline (M0), 6 months (M6), and 12 months (M12).

    Clinical evolution will be assessed using the MINI-S questionnaire administered at baseline (M0), 6 months (M6), and 12 months (M12). Descriptive analyses of questionnaire responses will be performed at each study time point. Only items related to the participant's current clinical state will be considered.

  5. Readiness for Transition to Adult Psychiatric Care

    Time frame: Baseline (M0) and 6 months (M6).

    The participant's readiness for transition to adult psychiatric care will be assessed using the Transition Readiness and Appropriateness Measure (TRAM) questionnaire administered before transition at baseline (M0) and 6 months (M6).

  6. Continuity of Psychiatric Care at 12 Months

    Time frame: 12 months (M12).

    Continuity of psychiatric care will be assessed at 12 months (M12). Continuity will be considered achieved if the participant has a defined psychiatric care plan at 12 months or has achieved clinical recovery and no longer requires psychiatric follow-up. The outcome will be recorded as a binary variable (Yes/No) based on the investigator's assessment.

  7. WHOQOL-BREF Quality of Life Score

    Time frame: Baseline (M0), 6 months (M6), and 12 months (M12).

    Quality of life will be assessed using the WHOQOL-BREF questionnaire administered at baseline (M0), 6 months (M6), and 12 months (M12). Changes in questionnaire scores over time will be described

  8. Psychosocial Functioning

    Time frame: Baseline (M0), 6 months (M6), and 12 months (M12).

    Psychosocial functioning will be assessed using the HoNOSCA questionnaire administered at baseline (M0), 6 months (M6), and 12 months (M12). Changes in questionnaire scores over time will be described.

  9. Outcome of Transition to Adult Psychiatric Care

    Time frame: 12 months (M12).

    The outcome of the transition to adult psychiatric care will be assessed using the Transition Related Outcome Measure (TROM) questionnaire administered after transition at 12 months (M12).

Study contacts

Contact information is provided by the study sponsor or research team.

ALINE JOULIE

CONTACT

[email protected]

+33492030520

Louis-Emilie Dumas, Child and adolescent psychiatr

CONTACT

[email protected]

+33 4 92030372 ext. +33

Sponsors and collaborators

Lead sponsor

Fondation Lenval

Other

Registry information

Acronym: Odysee3

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jul 16, 2025
Registry last updated
Jul 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.